Common stock of the merged company, Celularity, Inc., to commence trading on the Nasdaq Capital...
The Brain Mapping Foundation and the Society for Brain Mapping and Therapeutics to celebrate this...
Arthrex to receive exclusive rights to distribute and commercialize Celularity’s placental-derived biomaterial products for orthopedics...
No dose limiting toxicity to date with outpatient administration of three doses (Days 0, 7...
Pharmaceutical industry veteran brings more than 20 years of business and technical operations experience across...
Celularity to leverage Palantir’s next generation software and computational capabilities with their deep cellular data...
NEW YORK, April 16, 2021 /PRNewswire/ — On April 14, 2021, GX Acquisition Corp. (“GX”) (NASDAQ: “GXGX”), provided information...
On Tuesday, Celularity received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA)...
FLORHAM PARK, N.J., April 13, 2021 (GLOBE NEWSWIRE) — Celularity Inc. (“Celularity”), a clinical-stage biotechnology...
Presentations to showcase updates related to multiple Celularity programs in immuno-oncology and infectious disease FLORHAM...
FLORHAM PARK, N.J., March 18, 2021 (GLOBE NEWSWIRE) — Celularity Inc. (“Celularity”), a clinical-stage biotechnology...
FLORHAM PARK, N.J., March 09, 2021 (GLOBE NEWSWIRE) — Celularity Inc. (“Celularity”), a clinical-stage biotechnology...
FLORHAM PARK, N.J., Jan. 20, 2021 /PRNewswire/ — Celularity Inc., a clinical stage cell therapeutics company focused on...
FLORHAM PARK, N.J., Jan. 13, 2021 /PRNewswire/ — Celularity Inc., a clinical-stage cell therapeutics company focused on the...
Thank you for joining the conference call to introduce the proposed merger agreement between GX...
Your browser does not support the audio element. TranscriptThank you for joining the conference call...
Celularity has entered into a definitive merger agreement with GX Acquisition Corp. (Nasdaq: “GXGX”); upon...
FLORHAM PARK, N.J., Dec. 1, 2020 /PRNewswire/ — Celularity announced today that the independent Data Monitoring Committee (DMC) completed...
Celularity announced today that the first patient was dosed in a Phase I/II study of human placental hematopoietic stem cell derived NK cells (CYNK-001) for the treatment of adults with COVID-19 as part of a national clinical trial. The patient was treated at UC Irvine in California, the first CA site to open for patient enrollment with support from a COVID-19 Project grant awarded to Celularity by the California Institute for Regenerative Medicine (CIRM). Participating trial sites include Hackensack University Medical Center and Atlantic Health in New Jersey, MultiCare Health System in Washington State, Banner University Medical Center Phoenix in Arizona, the University of Arkansas in Arkansas, and UC Davis in California. The Principal Investigator is Corey Casper, M.D., MPH, of the Infectious Disease Research Institute (IDRI) ClinicalTrials.gov Identifier: NCT04365101.
Celularity, Inc. (”Celularity” or “the Company”) today announced that it has sold its UltraMIST® Ultrasound...